Kosaka M, Fujino H, Tsuge M, Yamaoka K, Fujii Y, Uchikawa S
J Gastroenterol. 2025; .
PMID: 39841247
DOI: 10.1007/s00535-025-02211-5.
Zhang J, Yu S, Zhu K, Li S, Huang Y
Front Med (Lausanne). 2025; 11():1464981.
PMID: 39776842
PMC: 11703914.
DOI: 10.3389/fmed.2024.1464981.
Bao H, Murakami S, Tsuge M, Uchida T, Uchikawa S, Fujino H
Viruses. 2024; 16(11).
PMID: 39599858
PMC: 11598975.
DOI: 10.3390/v16111743.
Tsuge M
Viruses. 2021; 13(10).
PMID: 34696350
PMC: 8541657.
DOI: 10.3390/v13101920.
Lin M, Guo R, Ma C, Zeng D, Su Z
Open Forum Infect Dis. 2021; 8(2):ofab028.
PMID: 33614817
PMC: 7885859.
DOI: 10.1093/ofid/ofab028.
Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index.
Liu T, Huang C, Yeh M, Tsai P, Jang T, Huang J
BMJ Open Gastroenterol. 2020; 7(1).
PMID: 33323472
PMC: 7745320.
DOI: 10.1136/bmjgast-2020-000543.
Identification of key genes and pathways associated with different immune statuses of hepatitis B virus infection.
Jin J, Xu H, Wu R, Gao N, Wu N, Li S
J Cell Mol Med. 2019; 23(11):7474-7489.
PMID: 31565863
PMC: 6815815.
DOI: 10.1111/jcmm.14616.
The Hepatitis B Surface Antigen Binding Protein: An Immunoglobulin G Constant Region-Like Protein That Interacts With HBV Envelop Proteins and Mediates HBV Entry.
Sun Y, Wang S, Yi Y, Zhang J, Duan Z, Yuan K
Front Cell Infect Microbiol. 2018; 8:338.
PMID: 30319994
PMC: 6167546.
DOI: 10.3389/fcimb.2018.00338.
Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M, Uchida T, Hiraga N, Kan H, Makokha G, Abe-Chayama H
Antimicrob Agents Chemother. 2017; 61(6).
PMID: 28373196
PMC: 5444133.
DOI: 10.1128/AAC.00183-17.
Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection.
Tsuge M, Hiraga N, Uchida T, Kan H, Miyaki E, Masaki K
J Gastroenterol. 2016; 51(11):1073-1080.
PMID: 26943168
DOI: 10.1007/s00535-016-1189-x.
Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B.
Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X
Saudi J Gastroenterol. 2015; 21(4):245-53.
PMID: 26228369
PMC: 4542424.
DOI: 10.4103/1319-3767.161645.
Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B.
Jun C, Hong H, Chung M, Park S, Bum Cho S, Park C
World J Gastroenterol. 2013; 19(40):6834-41.
PMID: 24187458
PMC: 3812482.
DOI: 10.3748/wjg.v19.i40.6834.
Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea.
Yue P, Wong Y, Wong K, Tsoi Y, Leung K
Chin Med. 2013; 8(1):21.
PMID: 24180549
PMC: 3819176.
DOI: 10.1186/1749-8546-8-21.
Clinical profile, genotype and management updates of hepatitis B virus.
Kumar A, Dwivedi M, Misra S, Narang S, Tiwari B, Pandey R
Indian J Virol. 2013; 22(1):1-10.
PMID: 23637496
PMC: 3550728.
DOI: 10.1007/s13337-011-0037-0.
Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.
Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N
J Gastroenterol. 2013; 48(10):1188-204.
PMID: 23397114
DOI: 10.1007/s00535-012-0737-2.
Surrogate markers of efficacy for medical treatment of viral hepatitis.
Block T, London W
Biotechnol Healthc. 2013; 1(5):42-8.
PMID: 23396674
PMC: 3564290.
Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck.
Kosinska A, Zhang E, Lu M, Roggendorf M
Hepat Res Treat. 2010; 2010:817580.
PMID: 21188201
PMC: 3003998.
DOI: 10.1155/2010/817580.
Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.
Mitsui F, Tsuge M, Kimura T, Kitamura S, Abe H, Saneto H
Antimicrob Agents Chemother. 2010; 54(8):3205-11.
PMID: 20498322
PMC: 2916322.
DOI: 10.1128/AAC.01372-09.
Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.
Chen E, Wang L, Lei J, Xu L, Tang H
Virol J. 2009; 6:163.
PMID: 19818142
PMC: 2764700.
DOI: 10.1186/1743-422X-6-163.
Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.
Piratvisuth T, Lau G, Chao Y, Jin R, Chutaputti A, Zhang Q
Hepatol Int. 2009; 2(1):102-10.
PMID: 19669285
PMC: 2716864.
DOI: 10.1007/s12072-007-9022-5.
